Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study

• Published in: BMC neurology 2019-09, Vol.19 (1), p.224-224, Article 224
• Main Authors: LoRusso, Samantha, Johnson, Nicholas E, McDermott, Michael P, Eichinger, Katy, Butterfield, Russell J, Carraro, Elena, Higgs, Kiley, Lewis, Leann, Mul, Karlien, Sacconi, Sabrina, Sansone, Valeria A, Shieh, Perry, van Engelen, Baziel, Wagner, Kathryn, Wang, Leo, Statland, Jeffrey M, Tawil, Rabi
• Format: Article
• Language: English
• Subjects: Analysis; Anopheles; Applied kinesiology; Arm; Biological markers; Biomarkers; Biomarkers - metabolism; Care and treatment; Clinical trial; Clinical trials; Disease; Disease Progression; DNA; Drug development; Drug Development - methods; Drugs; Dual energy X-ray absorptiometry; Electric currents; Electrical impedance; Electrical impedance Myography; Electromyography; Epigenetics; Facioscapulohumeral muscular dystrophy; FDA approval; Functional testing; Gene mutation; Genes; Genetic aspects; Genetic factors; Genetic research; Humans; Longitudinal Studies; Medical research; Muscular dystrophy; Muscular Dystrophy, Facioscapulohumeral - drug therapy; Muscular Dystrophy, Facioscapulohumeral - genetics; Mutation; Neuromuscular diseases; Outcome measures; Prospective Studies; R&D; Reproducibility of Results; Research & development; Researchers; Ribonucleic acid; Risk factors; RNA; Studies; Study Protocol; Therapeutics
• ISSN: 1471-2377; 1471-2377
• DOI: 10.1186/s12883-019-1452-x

Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly-inherited progressive muscular dystrophy caused by de-repression of the DUX4 gene, which causes disease by a toxic-gain-of-function. As molecularly targeted drugs move from preclinical testing into human trials, it is essential that we validate clinical trial tools and methodology to facilitate the drug development process. The primary goal of this study is to hasten drug development for FSHD by validating two novel clinical outcome assessments (COAs) and refining clinical trial strategies. We will perform an 18-month longitudinal study in 220 genetically confirmed and clinically affected participants using our FSHD Clinical Trial Research Network, comprised of 8 sites in the United States, and 3 collaborating sites in Europe. Visits occur at baseline and months 3, 12, and 18. At each visit we will collect: 1) a novel FSHD functional composite COA made up of 18 evaluator-administered motor tasks in the domains of shoulder/arm, hand, core/abdominal, leg, and balance function; and 2) electrical impedance myography as a novel muscle quality biomarker (US sites). Other COAs include 1) Domain 1 of the Motor Function Measure; 2) Reachable workspace; 3) orofacial strength using the Iowa Oral Performance Instrument; 4) lean muscle mass using dual-energy X-ray absorptiometry (DEXA); 5) strength as measured by quantitative myometry and manual muscle testing; and 6) the FSHD Health Index and other patient-reported outcomes. Plasma, DNA, RNA, and serum will be collected for future biomarker studies. We will use an industry standard multi-site training plan. We will evaluate the test-retest reliability, validity, and sensitivity to disease progression, and minimal clinically important changes of our new COAs. We will assess associations between demographic and genetic factors and the rate of disease progression to inform refinement of eligibility criteria for future clinical trials. To the best of our knowledge, this is the largest collaborative study of patients with FSHD performed in the US and Europe. The results of this study will enable more efficient clinical trial design. During the conduct of the study, relevant data will be made available for investigators or companies pursuing novel FSHD therapeutics. clinicaltrials.gov NCT03458832; Date of registration: 1/11/2018.